My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Wellbeing Digital Sciences Inc (OP:KONEF)

N/A UNCHANGED

Last Price Updated: 3:57 PM EST, Mar 6, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Wellbeing Digital Sciences Inc

< Previous 1 2 Next >

World's Largest Psychedelics Conference Sheds Light On Alternative Mental Health Therapies, Boasts 12K Attendees ↗

June 26, 2023

The Multidisciplinary Association for Psychedelic Studies (MAPS) sponsored a Psychedelic Science conference in Denver last week, which gathered over 12,000 people from the entire psy

Via Benzinga

Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More ↗

March 13, 2023

Major Depressive Disorder: Small Pharma’s Phase 2 DMT Trial, BetterLife’s Preclinical LSD Trial

Via Benzinga

Another Company Approved To Begin Production Of Psychedelics Under Canadian Dealers License ↗

March 09, 2023

A Contract Research Organization (CRO) and a wholly-owned subsidiary of Wellbeing Digital Sciences Inc.

Via Benzinga

Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person ↗

March 08, 2023

This year’s edition of the Benzinga Psychedelics Capital Conference, THE place to be for those interested or already involved in the space, will take place on April 13, following our established...

Via Benzinga

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More ↗

February 21, 2023

Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and...

Via Benzinga

Wellbeing Digital Net Loss Continues To Grow: Q2 Reaches $5.15M, Up By 552% YoY ↗

March 18, 2022

Wellbeing Digital Sciences Inc. (OTCQB:KONEF

Via Benzinga

Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder ↗

February 14, 2023

Wellbeing Digital (OTC: KONEF) subsidiary KGK Sciences will advance with the first-ever Phase 2a clinical trial assessing repetitive, oral microdose psilocybin therapy for Fragile X Syndrome (FXS), a...

Via Benzinga

Women's Footprint In Psychedelics Is Undeniable, Benzinga's Psychedelics Advisory Council's Six New Trailblazers ↗

January 30, 2023

In its capacity as a financial news and media outlet, Benzinga has added six new members to its Psychedelics Advisory Council.

Via Benzinga

First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval ↗

December 27, 2022

The partnership leading the way on psilocybin therapy for Fragile X Syndrome (FXS), the major genetic cause of Autism Spectrum Disorder (ASD), has received approval from Health Canada in the form of a...

Via Benzinga

Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project ↗

December 06, 2022

Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and...

Via Benzinga

Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial ↗

November 30, 2022

Psychedelics biotechs Nova Mentis Life Science Corp. (OTCQB: NMLSF) and Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Sciences Inc.

Via Benzinga

Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More ↗

November 21, 2022

Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy

Via Benzinga

Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial ↗

November 17, 2022

Psychedelics company Wellbeing Digital Sciences Inc. (OTC: KONEF)’s subsidiary KGK Science Inc. has entered into a research services agreement with Canadian-based biotech Nova Mentis Life Science...

Via Benzinga

Successful Study On Transdermal CBD & THC Delivery Presents Benefits For Treating Chronic Conditions ↗

November 15, 2022

Wellbeing Digital Sciences Inc. (NEO: MEDI) (OTC: KONEF) (FRA: SQ2), an evidence-based mental healthcare company announced that its wholl

Via Benzinga

Psyched: Top Psychedelics Execs., 50% Of Americans Support Medical Psychedelics, Cary Grant's LSD Therapy & More ↗

November 01, 2022

15 Global Psychedelics Executives To Keep An Eye On In 2022

Via Benzinga

Pathway Health To Acquire IRP Health From Wellbeing Digital Sciences ↗

October 27, 2022

Wellbeing Digital Sciences Inc.

Via Benzinga

Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More ↗

October 07, 2022

Alberta Becomes The First Canadian Province To Regulate Psychedelics-Assisted Therapy

Via Benzinga

Ketamine Therapy At Your Doorstep, Growing Number Of Clinics Offer This Treatment Option ↗

October 05, 2022

Being the sole psychedelic legally available as medicine, ketamine-assisted therapy services are expanding at a rapid pace across the U.S.

Via Benzinga

Wellbeing Digital Reports 4Q Finances, 'Three Key Pillars' Stay Strong ↗

September 16, 2022

Wellbeing Digital Sciences Inc. (OTC: KONEF) filed its financial results for the quarter ended July 31, 2022 and provided some insight on their most recent businesses. Numbers for the selected period...

Via Benzinga

World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them ↗

August 30, 2022

The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business...

Via Benzinga

KGK Sciences And Halucenex Sign Contract For Phase II Clinical Trial On Psilocybin For PTSD ↗

July 21, 2022

KGK Sciences Inc., a subsidiary company of psychedelics healthcare researcher and provider Wellbeing Digital Sciences Inc.

Via Benzinga

Wellbeing Digital Introduces Women In Psychedelics, A Network For Female Minds In Psychedelics ↗

July 18, 2022

Mental healthcare company Wellbeing Digital Sciences Inc. (OTC: KONEF) and its subsidiary KGK Science Inc. are the founding sponsors of the Women in Psychedelics Network, also known as “WIP.”

Via Benzinga

Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today ↗

March 15, 2022

GAINERS: Mind Medicine (NASDAQ:

Via Benzinga

Wellbeing Digital, Small Pharma Among Top Psychedelic Movers Of Today ↗

March 14, 2022

GAINERS: Wellbeing Digital (OTC:

Via Benzinga

Psychedelic Stock Gainers And Losers From March 7, 2022 ↗

March 07, 2022

GAINERS: GH Research (NASDAQ:

Via Benzinga

Psychedelic Stock Gainers And Losers From March 4, 2022 ↗

March 04, 2022

GAINERS: Wellbeing Digital (OTC:

Via Benzinga

Psychedelic Stock Gainers And Losers From March 1, 2022 ↗

March 01, 2022

GAINERS: Cybin (AMEX:

Via Benzinga

Psychedelic Stock Gainers And Losers From February 28, 2022 ↗

February 28, 2022

GAINERS: Wellbeing Digital (OTC:

Via Benzinga

Psychedelic Stock Gainers And Losers From February 14, 2022 ↗

February 14, 2022

GAINERS: Wellbeing Digital (OTC:

Via Benzinga

Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market ↗

February 08, 2022

Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.